Skip to main content
. 2020 Oct 21;2020(10):CD013750. doi: 10.1002/14651858.CD013750

12.3. Analysis.

12.3

Comparison 12: Platinum vs non‐platinum regimens (sensitivity analysis 5: Analyses 1 repeated but with Carey 2012 excluded), Outcome 3: Objective tumour response rate (assessable participants)